[go: up one dir, main page]

DE60140794D1 - Von casein abgeleitete peptide und deren anwendung für die therapie - Google Patents

Von casein abgeleitete peptide und deren anwendung für die therapie

Info

Publication number
DE60140794D1
DE60140794D1 DE60140794T DE60140794T DE60140794D1 DE 60140794 D1 DE60140794 D1 DE 60140794D1 DE 60140794 T DE60140794 T DE 60140794T DE 60140794 T DE60140794 T DE 60140794T DE 60140794 D1 DE60140794 D1 DE 60140794D1
Authority
DE
Germany
Prior art keywords
peptides
casein
stimulating
derived
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60140794T
Other languages
English (en)
Inventor
Zvi Sidelman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Peptera Pharmaceuticals Ltd
Original Assignee
Peptera Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peptera Pharmaceuticals Ltd filed Critical Peptera Pharmaceuticals Ltd
Application granted granted Critical
Publication of DE60140794D1 publication Critical patent/DE60140794D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4732—Casein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
DE60140794T 2000-03-01 2001-03-01 Von casein abgeleitete peptide und deren anwendung für die therapie Expired - Lifetime DE60140794D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL13483000A IL134830A0 (en) 2000-03-01 2000-03-01 Peptides and immunostimulatory and anti-bacterial pharmaceutical compositions containing them
PCT/IL2001/000198 WO2001064234A1 (en) 2000-03-01 2001-03-01 Casein derived peptides and uses thereof in therapy

Publications (1)

Publication Number Publication Date
DE60140794D1 true DE60140794D1 (de) 2010-01-28

Family

ID=11073892

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60140794T Expired - Lifetime DE60140794D1 (de) 2000-03-01 2001-03-01 Von casein abgeleitete peptide und deren anwendung für die therapie

Country Status (21)

Country Link
US (6) US20020147144A1 (de)
EP (1) EP1261360B1 (de)
JP (1) JP2003528827A (de)
KR (1) KR20030025907A (de)
CN (1) CN1427725A (de)
AT (1) ATE451929T1 (de)
AU (1) AU782662B2 (de)
BR (1) BR0109027A (de)
CA (1) CA2401550A1 (de)
CZ (1) CZ20022915A3 (de)
DE (1) DE60140794D1 (de)
DK (1) DK1261360T3 (de)
EA (3) EA005579B1 (de)
HU (1) HUP0301003A3 (de)
IL (2) IL134830A0 (de)
MX (1) MXPA02008569A (de)
NO (1) NO20024157L (de)
NZ (1) NZ521016A (de)
PL (1) PL361307A1 (de)
WO (1) WO2001064234A1 (de)
ZA (1) ZA200206842B (de)

Families Citing this family (147)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04001890A (es) * 2001-08-30 2004-06-18 Chay 13 Medical Res Group N V Peptidos derivados de caseina y sus usos en terapia.
WO2003067904A2 (en) * 2002-02-06 2003-08-14 University Of North Carolina At Chapel Hill High-throughput cell identification and isolation method and apparatus
EP1359157A1 (de) * 2002-04-29 2003-11-05 Société des Produits Nestlé S.A. Metalloproteinase-Hemmstoff
AU2003299568B2 (en) * 2002-11-27 2010-07-22 Ampio Pharmaceuticals, Inc. Treatment of diseases and conditions mediated by increased phosphorylation
GB0313892D0 (en) * 2003-06-16 2003-07-23 Hannah Res Inst Control of lactation
BRPI0507822A (pt) * 2004-03-01 2007-07-10 Peptera Pharmaceuticals Ltd método e composição farmacêutica para a prevenção ou o tratamento de uma doença ou uma condição autoimune ou infecciosa, método e composição farmacêutica para a prevenção ou o tratamento de uma doença ou uma condição do sangue, método e composição farmacêutica para modular a formação de células do sangue, método e composição farmacêutica para intensificar a mobilização periférico da célula tronco, método e composição farmacêutica para a prevenção ou o tratamento de uma doença ou uma condição metabólica, método e composição farmacêutica para a prevenção ou o tratamento das condições associadas com doses mieloablativas de quimioradioterapia suportadas pelo transplante autólogo de medula óssea ou de células tronco do sangue periférico (asct) ou pelo transplante alogenéico de medula óssea (bmt), método e composição farmacêutica para aumentar o efeito de um fator estimulante de células do sangue, método e composição farmacêutica para intensificar a colonização de células tronco do sangue doadas em um receptor mieloablatado, método e composição farmacêutica para a prevenção ou o tratamento de uma doença ou uma condição bacteriana, composição farmacêutica para o tratamento ou a prevenção de uma indicação selecionada do grupo que consiste em doença ou condição autoimune, doença viral, infecção viral, doença hematológica, deficiências hematológicas, trombocitopenia, pancitopenia, granulopenia, hiperlipidemia, hipercolesterolemia, glucosuria, hiperglicemia, diabetes, aids, hiv-1, distúrbios de células t auxiliares, deficiências de células dendrìticas, deficiências de macrofagos, distúrbios de células tronco hematopoiéticas incluindo distúrbios com plaquetas, linfócitos, células do plasma e neutrófilos, condições pré-leucêmicas, condições leucêmicas, distúrbios do sistema imunológico resultantes da terapia de quimioterapia ou de radiação, distúrbios do sistema imunológico humano resultantes do tratamento das doenças de deficiência imunológica e infecções bacterianas, composição farmacêutica para o tratamento ou a prevenção de um indicação selecionada do grupo que consiste em doença hematológica, deficiências hematológicas, trombocitopenia, pancitopenia, granulopenia, deficiências de células dendrìticas, deficiências de macrofagos, distúrbios de células tronco hematopoiéticas incluindo distúrbios com plaquetas, linfócitos, células do plasma e neutrófilos, condições pré-leucêmicas, condições leucêmicas, sìndrome mielodisplástiacas, malignidades não mielóides, anemia plástica e insuficiência da medula óssea, peptìdeo purificado, peptìdeo quimérico purificado, peptìdeo quimérico, composição farmacêutica, composição farmacêutica para a prevenção ou o tratamento de uma condição associada com um agente infeccioso de sars, método de processamento a baixa temperatura de hidrolisato proteolìtico de caseìna e hidrolisato de proteìna de caseìna
UY28769A1 (es) 2004-03-30 2005-09-30 Monsanto Technology Llc Métodos para controlar agentes patógenos en plantas usando n-fosfonometilglicina
WO2005099724A2 (en) * 2004-04-13 2005-10-27 Parallel Solutions, Inc. Functionalized water-soluble polyphosphazene and uses thereof as modifiers of biological agents
US9000040B2 (en) 2004-09-28 2015-04-07 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US9012506B2 (en) 2004-09-28 2015-04-21 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
EP1819297B1 (de) 2004-09-28 2015-01-14 Atrium Medical Corporation Uv-gehärtetes gel und herstellungsverfahren
GB0423352D0 (en) * 2004-10-21 2004-11-24 Hannah Res Inst "Control of mammary cell number"
KR20130122979A (ko) * 2005-05-02 2013-11-11 밀레우티스 엘티디. 카제인으로부터 유도된 펩티드로 구성된 약학 조성물 및 이를 이용하는 방법
ES2319475B1 (es) * 2005-06-08 2010-02-16 Consejo Superior Investig. Cientificas Peptidos bioactivos identificados en hidrolizados enzimaticos de caseinas lacteas y procedimiento de obtencion.
US11266607B2 (en) * 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
US9427423B2 (en) 2009-03-10 2016-08-30 Atrium Medical Corporation Fatty-acid based particles
US9278161B2 (en) 2005-09-28 2016-03-08 Atrium Medical Corporation Tissue-separating fatty acid adhesion barrier
CA2625183C (en) 2005-10-04 2019-09-03 Inimex Pharmaceuticals Inc. Novel peptides for treating and preventing immune-related disorders, including treating and preventing infection by modulating innate immunity
US20080118525A1 (en) * 2006-10-04 2008-05-22 Oreola Donini Novel peptides for treating and preventing immune-related disorders, including treating and preventing infection by modulating innate immunity
US20070086958A1 (en) * 2005-10-14 2007-04-19 Medafor, Incorporated Formation of medically useful gels comprising microporous particles and methods of use
GB2436328A (en) * 2006-03-22 2007-09-26 Regen Therapeutics Plc Peptide derived from colostrinin
BRPI0707042A2 (pt) * 2006-03-24 2011-04-12 Unilever Nv produto alimentìcio e uso
EP1836906B1 (de) * 2006-03-24 2009-07-01 Unilever N.V. Gesundes Nahrungsmittel
EP2124522B1 (de) * 2007-02-05 2011-11-16 National University of Singapore Mutmasslicher cytokininrezeptor und verfahren für seine verwendung
US8097712B2 (en) 2007-11-07 2012-01-17 Beelogics Inc. Compositions for conferring tolerance to viral disease in social insects, and the use thereof
WO2009113635A1 (ja) * 2008-03-12 2009-09-17 株式会社 資生堂 不全角化抑制剤、毛穴縮小剤又は肌荒れ防止・改善剤及びそれを配合した皮膚外用組成物
KR101355695B1 (ko) * 2009-02-06 2014-01-27 더 프록터 앤드 갬블 캄파니 붕괴성 수분-함유 캡슐
AU2010233097B2 (en) * 2009-04-10 2016-04-07 Abraxis Bioscience, Llc Nanoparticle formulations and uses thereof
EP2427179A4 (de) 2009-05-04 2013-09-11 Psivida Inc Poröse partikel zur freisetzung von silicium-arzneimitteln
US10555527B2 (en) * 2009-05-18 2020-02-11 Monsanto Technology Llc Use of glyphosate for disease suppression and yield enhancement in soybean
GB0912481D0 (en) 2009-07-17 2009-08-26 Reckitt Benckiser Healthcare I Skincare compositions
US20110038910A1 (en) 2009-08-11 2011-02-17 Atrium Medical Corporation Anti-infective antimicrobial-containing biomaterials
US8962584B2 (en) 2009-10-14 2015-02-24 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Compositions for controlling Varroa mites in bees
JP5908846B2 (ja) * 2009-12-29 2016-04-26 ダブリュー・アール・グレース・アンド・カンパニー−コーンＷ Ｒ Ｇｒａｃｅ ＆ Ｃｏ−Ｃｏｎｎ 所望の程度の隠蔽性を有する膜を形成するための組成物、並びにそれを製造及び使用する方法
KR20120112849A (ko) * 2010-02-04 2012-10-11 아이에스피이 인베스트먼츠 인코포레이팃드 무수 선스크린 포뮬레이션용 자가 개조성 중합체
EP2536267B1 (de) * 2010-02-18 2015-07-22 Athenix Corp. Axmi221z-, axmi222z-, axmi223z-, axmi224z- und axmi225z-delta-endotoxin-gene sowie anwendungsverfahren dafür
CA2790023A1 (en) * 2010-02-18 2011-08-25 Athenix Corp. Axmi218, axmi219, axmi220, axmi226, axmi227, axmi228, axmi229, axmi230, and axmi231 delta-endotoxin genes and methods for their use
ES2641642T3 (es) 2010-03-08 2017-11-10 Monsanto Technology Llc Moléculas de polinucleótido para regulación génica en plantas
FR2958155B1 (fr) * 2010-04-02 2012-04-20 Oreal Composition de decoloration comprenant un sel peroxygene dans une base fortement riche en corps gras
WO2011137563A1 (en) 2010-05-07 2011-11-10 Unilever Plc High solvent content emulsions
AU2011261580B2 (en) 2010-06-04 2013-12-19 Monsanto Technology Llc Transgenic brassica event MON 88302 and methods of use thereof
WO2012009707A2 (en) 2010-07-16 2012-01-19 Atrium Medical Corporation Composition and methods for altering the rate of hydrolysis of cured oil-based materials
CA2807171A1 (en) * 2010-08-19 2012-02-23 Pioneer Hi-Bred International, Inc. Novel bacillus thuringiensis gene with lepidopteran activity
US9757374B2 (en) 2010-10-28 2017-09-12 Aequus Pharmaceuticals Inc. Aripiprazole compositions and methods for its transdermal delivery
WO2012058091A2 (en) * 2010-10-28 2012-05-03 Alpha To Omega Pharmaceutical Consultants, Inc. Aripiprazole compositions and methods for its transdermal delivery
EP2635255B1 (de) 2010-11-01 2019-08-21 EyePoint Pharmaceuticals US, Inc. Biologisch abbaubare vorrichtungen auf siliciumbasis zur abgabe therapeutischer mittel
MX2013014098A (es) * 2011-06-04 2014-10-14 Texas A & M Univ Sys Composiciones, sistemas, metodos, microorgnismos, y plantas de transformacion de patata.
EP2742059A1 (de) * 2011-08-12 2014-06-18 Bayer CropScience NV Schliesszellspezifische expression von transgenen in baumwolle
BR112014005958A2 (pt) 2011-09-13 2020-10-13 Monsanto Technology Llc métodos e composições químicas agrícolas para controle de planta, método de redução de expressão de um gene accase em uma planta, cassete de expressão microbiana, método para fazer um polinucleotídeo, método de identificação de polinucleotídeos úteis na modulação de expressão do gene accase e composição herbicida
US10806146B2 (en) 2011-09-13 2020-10-20 Monsanto Technology Llc Methods and compositions for weed control
US10829828B2 (en) 2011-09-13 2020-11-10 Monsanto Technology Llc Methods and compositions for weed control
UY34328A (es) 2011-09-13 2013-04-30 Monsanto Technology Llc ?composiciones y métodos para controlar malezas comprendiendo un polinucleótido y agente de transferencia, y que modulan protoporfirinógeno ix oxidasa?.
CN107739737A (zh) 2011-09-13 2018-02-27 孟山都技术公司 用于杂草控制的方法和组合物
US9840715B1 (en) 2011-09-13 2017-12-12 Monsanto Technology Llc Methods and compositions for delaying senescence and improving disease tolerance and yield in plants
US10760086B2 (en) 2011-09-13 2020-09-01 Monsanto Technology Llc Methods and compositions for weed control
WO2013040057A1 (en) 2011-09-13 2013-03-21 Monsanto Technology Llc Methods and compositions for weed control
US9920326B1 (en) 2011-09-14 2018-03-20 Monsanto Technology Llc Methods and compositions for increasing invertase activity in plants
BR112014007366B1 (pt) * 2011-10-05 2020-09-15 Dupont Nutrition Usa, Inc Processo para fabricar uma composição estabilizadora compreendendo extrusão em duas etapas, composição estabilizadora de celulose microcristalina e produto alimentício comestível e suspensão industrial compreendendo a mesma
US9433660B2 (en) * 2012-08-03 2016-09-06 Msm Innovations, Inc Method and kit for bowel preparation
US9492363B1 (en) * 2012-01-16 2016-11-15 American Spraytech, L.L.C. Aerosol sprayable color composition
HK1204287A1 (en) * 2012-01-27 2015-11-13 敏捷治疗公司 Transdermal hormone delivery
FR2988566B1 (fr) * 2012-03-28 2014-08-08 Yoplait France Compositions alimentaires pour stimuler la formation de tissu osseux
IN2014MN02404A (de) 2012-05-24 2015-08-21 Seeds Ltd Ab
US9701998B2 (en) 2012-12-14 2017-07-11 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10752949B2 (en) 2012-08-14 2020-08-25 10X Genomics, Inc. Methods and systems for processing polynucleotides
US9951386B2 (en) 2014-06-26 2018-04-24 10X Genomics, Inc. Methods and systems for processing polynucleotides
IN2015DN01126A (de) 2012-08-14 2015-06-26 10X Genomics Inc
US10273541B2 (en) 2012-08-14 2019-04-30 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10221442B2 (en) 2012-08-14 2019-03-05 10X Genomics, Inc. Compositions and methods for sample processing
US11591637B2 (en) 2012-08-14 2023-02-28 10X Genomics, Inc. Compositions and methods for sample processing
US10400280B2 (en) 2012-08-14 2019-09-03 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10323279B2 (en) 2012-08-14 2019-06-18 10X Genomics, Inc. Methods and systems for processing polynucleotides
US9617297B2 (en) * 2012-10-11 2017-04-11 The Regents Of The University Of California Apoplast wash fluid recovery for improved recombinant endoglucanase extraction in tabacco leaves
BR112015008706A2 (pt) 2012-10-18 2018-02-06 Monsanto Technology Llc métodos e composições para controle de praga de plantas
EP3567116A1 (de) 2012-12-14 2019-11-13 10X Genomics, Inc. Verfahren und systeme zur verarbeitung von polynukleotiden
US10533221B2 (en) 2012-12-14 2020-01-14 10X Genomics, Inc. Methods and systems for processing polynucleotides
US9206436B2 (en) * 2012-12-20 2015-12-08 Ut-Battelle, Llc Key gene regulating cell wall biosynthesis and recalcitrance in Populus, gene Y
US10683505B2 (en) 2013-01-01 2020-06-16 Monsanto Technology Llc Methods of introducing dsRNA to plant seeds for modulating gene expression
EA032406B1 (ru) 2013-01-01 2019-05-31 Эй.Би. СИДЗ ЛТД. СПОСОБЫ ВВЕДЕНИЯ дсРНК В СЕМЕНА РАСТЕНИЙ ДЛЯ МОДУЛЯЦИИ ЭКСПРЕССИИ ГЕНОВ
US10000767B2 (en) 2013-01-28 2018-06-19 Monsanto Technology Llc Methods and compositions for plant pest control
EP2954104B1 (de) 2013-02-08 2020-09-16 10X Genomics, Inc. Polynukleotid-strichcodegenerierung
US8961680B2 (en) * 2013-03-08 2015-02-24 Tbf Environmental Technology Inc. Solvent formulations
US20140271764A1 (en) * 2013-03-12 2014-09-18 Psivida Us, Inc. Bioerodible Silicon-Based Delivery Vehicles for Delivery of Therapeutic Agents
CA2905104A1 (en) 2013-03-13 2014-10-09 Monsanto Technology Llc Control of lolium species by topical application of herbicidal composition comprising dsrna
WO2014164761A1 (en) 2013-03-13 2014-10-09 Monsanto Technology Llc Methods and compositions for weed control
US20140283211A1 (en) 2013-03-14 2014-09-18 Monsanto Technology Llc Methods and Compositions for Plant Pest Control
US9345741B2 (en) 2013-03-15 2016-05-24 Mead Johnson Nutrition Company Nutritional composition containing a peptide component with adiponectin simulating properties and uses thereof
US9289461B2 (en) * 2013-03-15 2016-03-22 Mead Johnson Nutrition Company Reducing the risk of autoimmune disease
RU2705986C2 (ru) 2013-03-15 2019-11-13 Айпоинт Фармасьютикалз Юэс, Инк. Биоразлагаемые композиции на основе кремния для доставки терапевтических агентов
US10568328B2 (en) 2013-03-15 2020-02-25 Monsanto Technology Llc Methods and compositions for weed control
US9138455B2 (en) 2013-03-15 2015-09-22 Mead Johnson Nutrition Company Activating adiponectin by casein hydrolysate
US9345727B2 (en) 2013-03-15 2016-05-24 Mead Johnson Nutrition Company Nutritional compositions containing a peptide component and uses thereof
US8889633B2 (en) 2013-03-15 2014-11-18 Mead Johnson Nutrition Company Nutritional compositions containing a peptide component with anti-inflammatory properties and uses thereof
US9352020B2 (en) 2013-03-15 2016-05-31 Mead Johnson Nutrition Company Reducing proinflammatory response
CA2942000C (en) * 2013-03-15 2024-04-16 Maria Beug-Deeb Inc. Dba T&M Associates Methods and compositions for cleaning and disinfecting surfaces
CA2817728A1 (en) * 2013-05-31 2014-11-30 Pharmascience Inc. Abuse deterrent immediate release formulation
US9850496B2 (en) 2013-07-19 2017-12-26 Monsanto Technology Llc Compositions and methods for controlling Leptinotarsa
PL3030663T3 (pl) 2013-07-19 2020-04-30 Monsanto Technology Llc Kompozycje i sposoby kontroli leptinotarsa
LT3421033T (lt) * 2013-10-07 2022-11-10 Bristol-Myers Squibb Holdings Ireland Unlimited Company Atazanaviro ir kobicistato kompozicija, skirta živ gydymui
UY35817A (es) 2013-11-04 2015-05-29 Us Agriculture ?composiciones y métodos para controlar infestaciones de plagas y parásitos de los artrópodos?.
UA119253C2 (uk) 2013-12-10 2019-05-27 Біолоджикс, Інк. Спосіб боротьби із вірусом у кліща varroa та у бджіл
AR099092A1 (es) 2014-01-15 2016-06-29 Monsanto Technology Llc Métodos y composiciones para el control de malezas utilizando polinucleótidos epsps
ES2544153B1 (es) * 2014-02-24 2016-06-06 Ntd Labs, S.L. Uso de un hidrolizado de caseína como agente antiviral
EP3420809A1 (de) 2014-04-01 2019-01-02 Monsanto Technology LLC Zusammensetzungen und verfahren zur bekämpfung von insektenbefall
CN114534806B (zh) 2014-04-10 2024-03-29 10X基因组学有限公司 用于封装和分割试剂的流体装置、系统和方法及其应用
US10988764B2 (en) 2014-06-23 2021-04-27 Monsanto Technology Llc Compositions and methods for regulating gene expression via RNA interference
US11807857B2 (en) 2014-06-25 2023-11-07 Monsanto Technology Llc Methods and compositions for delivering nucleic acids to plant cells and regulating gene expression
US12312640B2 (en) 2014-06-26 2025-05-27 10X Genomics, Inc. Analysis of nucleic acid sequences
EP4053292A1 (de) 2014-06-26 2022-09-07 10X Genomics, Inc. Verfahren zur analyse von nukleinsäuren aus einzelzellen oder zellpopulationen
JP2017522866A (ja) 2014-06-26 2017-08-17 １０エックス ジェノミクス， インコーポレイテッド 核酸配列の分析
US20160008410A1 (en) 2014-07-08 2016-01-14 Mimedx Group, Inc. Micronized wharton's jelly
US20160022604A1 (en) * 2014-07-23 2016-01-28 Cadila Healthcare Limited Directly compressed ospemifene compositions
CN114009454A (zh) 2014-07-29 2022-02-08 孟山都技术公司 用于控制昆虫害虫的组合物和方法
KR102305346B1 (ko) * 2014-09-11 2021-09-28 겔리타 아게 젤라틴/펙틴 입자
MX2017003602A (es) 2014-09-17 2017-07-13 Lonza Ag Composiciones de desinfectante de peroxido de hidrogeno activado.
JP2017532042A (ja) 2014-10-29 2017-11-02 １０エックス ゲノミクス，インコーポレイテッド 標的化核酸配列決定のための方法及び組成物
US9975122B2 (en) 2014-11-05 2018-05-22 10X Genomics, Inc. Instrument systems for integrated sample processing
CA2972949A1 (en) * 2015-01-06 2016-07-14 Osamu Yamada Medicinal composition, blood treatment device, cosmetic, food and drink using combustion synthesis material
JP6769969B2 (ja) 2015-01-12 2020-10-14 １０エックス ジェノミクス， インコーポレイテッド 核酸配列決定ライブラリーを作製するためのプロセス及びシステム、並びにこれらを使用して作製したライブラリー
CN108064288B (zh) 2015-01-22 2021-11-26 孟山都技术公司 用于控制叶甲属的组合物和方法
US10697000B2 (en) 2015-02-24 2020-06-30 10X Genomics, Inc. Partition processing methods and systems
US11274343B2 (en) 2015-02-24 2022-03-15 10X Genomics, Inc. Methods and compositions for targeted nucleic acid sequence coverage
WO2016137804A1 (en) 2015-02-25 2016-09-01 The Procter & Gamble Company Fibrous structures comprising a surface softening composition
US20160303043A1 (en) * 2015-04-16 2016-10-20 Kate Somerville Skincare, LLC Self-foaming compositions and methods
AU2016270870A1 (en) 2015-06-02 2018-01-04 Monsanto Technology Llc Compositions and methods for delivery of a polynucleotide into a plant
WO2016196782A1 (en) 2015-06-03 2016-12-08 Monsanto Technology Llc Methods and compositions for introducing nucleic acids into plants
AR105299A1 (es) 2015-07-10 2017-09-20 Procter & Gamble Composición de cuidado de telas que comprende ésteres de poliol instaurados metatesizado
SG11201804086VA (en) 2015-12-04 2018-06-28 10X Genomics Inc Methods and compositions for nucleic acid analysis
WO2017197343A2 (en) 2016-05-12 2017-11-16 10X Genomics, Inc. Microfluidic on-chip filters
WO2017197338A1 (en) 2016-05-13 2017-11-16 10X Genomics, Inc. Microfluidic systems and methods of use
EP3481366B1 (de) * 2016-07-08 2022-07-27 The Gillette Company LLC Flüssige zusammensetzungen für haarentfernungsvorrichtungen mit metathesierten ungesättigten polyolestern
DE102016223333A1 (de) * 2016-11-24 2018-05-24 Henkel Ag & Co. Kgaa Alkalische Mittel zum Aufhellen von Haaren enthaltend Oxidationsmittel und spezielle Carbonsäureester als Keratinvernetzer
US10815525B2 (en) 2016-12-22 2020-10-27 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10550429B2 (en) 2016-12-22 2020-02-04 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10011872B1 (en) 2016-12-22 2018-07-03 10X Genomics, Inc. Methods and systems for processing polynucleotides
CN117512066A (zh) 2017-01-30 2024-02-06 10X基因组学有限公司 用于基于微滴的单细胞条形编码的方法和系统
US12264411B2 (en) 2017-01-30 2025-04-01 10X Genomics, Inc. Methods and systems for analysis
AU2018227842B2 (en) * 2017-03-01 2024-05-02 Arena Pharmaceuticals, Inc. Compositions comprising PGI2-receptor agonists and processes for the preparation thereof
US10398670B2 (en) * 2017-04-24 2019-09-03 Knoze Jr. Corporation Oral microbiota promotion for oral and/or sinus infections
EP3445876B1 (de) 2017-05-26 2023-07-05 10X Genomics, Inc. Einzelzellenanalyse von transposasezugänglichem chromatin
US10844372B2 (en) 2017-05-26 2020-11-24 10X Genomics, Inc. Single cell analysis of transposase accessible chromatin
US10471033B2 (en) * 2017-09-15 2019-11-12 Knoze Jr. Corporation Oral microbiota promotion for immune system associated inflammations
US12151014B2 (en) * 2017-09-18 2024-11-26 Mast Industries (Far East) Limited Gloss lip balm formulation
EP3625361A1 (de) 2017-11-15 2020-03-25 10X Genomics, Inc. Funktionalisierte gelperlen
US10829815B2 (en) 2017-11-17 2020-11-10 10X Genomics, Inc. Methods and systems for associating physical and genetic properties of biological particles
CN112262218B (zh) 2018-04-06 2024-11-08 10X基因组学有限公司 用于单细胞处理中的质量控制的系统和方法
US20220330599A1 (en) * 2019-09-16 2022-10-20 Kiverdi, Inc. Microbial Protein Hydrolysate Compositions and Methods of Making Same

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3764670A (en) * 1970-10-28 1973-10-09 Ministry Of Agriculture Polypeptidic anti-biotic substances derived from casein
US3778426A (en) * 1970-12-16 1973-12-11 Research Corp Therapeutically useful polypeptides
US4636384A (en) * 1982-06-03 1987-01-13 Stolle Research & Development Corporation Method for treating disorders of the vascular and pulmonary systems
US4959455A (en) * 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US5344820A (en) * 1987-05-15 1994-09-06 Snow Brand Milk Products Co., Ltd. Infection protectant
JP2631470B2 (ja) * 1987-05-15 1997-07-16 雪印乳業株式会社 感染防御剤
JP2805490B2 (ja) * 1989-02-07 1998-09-30 雪印乳業株式会社 細菌毒素中和剤
US5514646A (en) * 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
FR2686085B1 (fr) * 1992-01-10 1995-08-04 Agronomique Inst Nat Rech Peptides representant des fragments du cmp, anticorps diriges contre lesdits peptides, et leurs utilisations.
GB9310472D0 (en) * 1993-05-20 1993-07-07 Univ Warwick Phenylalanine-free protein and dna coding thereof
TW282398B (de) * 1993-12-22 1996-08-01 Bristol Myers Squibb Co
US5707968A (en) * 1994-05-26 1998-01-13 Abbott Laboratories Inhibition of attachment of H.influenzae to human cells
US5538952A (en) * 1994-05-26 1996-07-23 Abbott Laboratories Inhibition of infection of mammalian cells by respiratory syncytial virus
US5506209A (en) * 1994-05-26 1996-04-09 Abbott Laboratories Product for inhibition of infection of mammalian cells by respiratory syncytial virus
US5712250A (en) * 1994-09-16 1998-01-27 Abbott Laboratories Product for inhibition of human rotavirus infection
KR0140248B1 (ko) * 1995-03-23 1998-06-15 한상기 신규한 카제인 포스포펩티드, 그것을 포함하는 카제인 및 그 제조방법
US5985275A (en) * 1995-04-12 1999-11-16 New York Blood Center β-Lactoglobulin modified with aromatic anhydride compound for preventing HIV infection
US6570060B2 (en) * 1995-05-16 2003-05-27 Mclachlan Corran Norman Stuart Milk lacking β-casein A1
KR100221124B1 (ko) * 1996-09-23 1999-10-01 한상기 신규한 카제인 및 그 제조방법
US5830434A (en) * 1997-02-26 1998-11-03 Medical University Of South Carolina Foundation For Research Development Methods of treating non-insulin dependent diabetes mellitus with pancreatic polypeptide
JP4191261B2 (ja) * 1997-03-21 2008-12-03 雪印乳業株式会社 鉄カゼイン類分解物複合体及びその製造法
US6358508B1 (en) * 1997-06-11 2002-03-19 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor TR9
DE69820449T2 (de) * 1997-08-29 2005-03-10 The Brigham And Women's Hospital Inc., Boston T-zell-membranprotein (tirc7), davon abgeleitete peptide und antikörper und ihre verwendungen
AUPP051497A0 (en) * 1997-11-24 1997-12-18 University Of Melbourne, The Antimicrobial peptides
US5985575A (en) * 1998-05-20 1999-11-16 Wisconsin Alumni Research Foundation Tethered function assay for protein function
US6570606B1 (en) * 1998-05-29 2003-05-27 3Com Corporation Method and apparatus for controlling transmission of media signals over a data network in response to triggering events at participating stations
US6656471B1 (en) * 1998-11-17 2003-12-02 Board Of Regents, The University Of Texas System HIV-specific T-cell induction
GB9927603D0 (en) * 1999-11-22 2000-01-19 Nestle Sa Use of a milk protein hydrolysate in the treatment of diabetes
IL138946A0 (en) * 2000-10-11 2001-11-25 Compugen Ltd Method for the identification of peptides and proteins
EP1928473A4 (de) * 2005-09-28 2009-11-18 Dnp Canada Inc Kombination aus polychitosamin und fibrat zur prävention und behandlung von hyperlipidämie
US8865876B2 (en) * 2008-06-02 2014-10-21 California Institute Of Technology Engineered lectin oligomers with antiviral activity

Also Published As

Publication number Publication date
EA007217B1 (ru) 2006-08-25
JP2003528827A (ja) 2003-09-30
IL151351A (en) 2012-04-30
IL134830A0 (en) 2001-05-20
EA005579B1 (ru) 2005-04-28
EA007814B1 (ru) 2007-02-27
ZA200206842B (en) 2003-07-28
US7741274B2 (en) 2010-06-22
EP1261360A1 (de) 2002-12-04
HUP0301003A2 (hu) 2003-07-28
CN1427725A (zh) 2003-07-02
ATE451929T1 (de) 2010-01-15
EA200400376A1 (ru) 2005-06-30
AU782662B2 (en) 2005-08-18
US8735348B2 (en) 2014-05-27
EA200200820A1 (ru) 2003-08-28
WO2001064234A1 (en) 2001-09-07
US20020147144A1 (en) 2002-10-10
EP1261360B1 (de) 2009-12-16
US20070161557A1 (en) 2007-07-12
BR0109027A (pt) 2003-06-03
EA200401467A1 (ru) 2005-04-28
US20130096073A1 (en) 2013-04-18
CA2401550A1 (en) 2001-09-07
US20100317601A1 (en) 2010-12-16
PL361307A1 (en) 2004-10-04
NO20024157L (no) 2002-10-30
KR20030025907A (ko) 2003-03-29
AU3596201A (en) 2001-09-12
NO20024157D0 (no) 2002-08-30
EP1261360A4 (de) 2004-03-10
CZ20022915A3 (cs) 2003-03-12
NZ521016A (en) 2005-08-26
US20090192081A1 (en) 2009-07-30
US20100298216A1 (en) 2010-11-25
HUP0301003A3 (en) 2007-08-28
MXPA02008569A (es) 2003-02-24
DK1261360T3 (da) 2010-05-03

Similar Documents

Publication Publication Date Title
DE60140794D1 (de) Von casein abgeleitete peptide und deren anwendung für die therapie
WO2005081628A3 (en) Casein derived peptides and therapeutic uses thereof
EP1005376A4 (de) Methoden und zusammensetzungen zum einsatz in einer gentherapie zur behandlung von hämophilie
ATE198050T1 (de) Therapeutische anwendungen von bpi-protein- produkten zur behandlung von humaner meningococcämia
DE69838986D1 (de) Polypeptide, deren herstellung und verwendung
ATE242633T1 (de) Dialkylfumarate zur behandlung von autoimmunerkrankungen
ATE63748T1 (de) Enzymwiderstandsfaehige immunomodulatorische peptide.
TR199801649T2 (xx) Ba����kl�k mod�lasyonu i�in farmaz�tik bile�imler.
ATE231549T1 (de) Verfahren zur konservierung von infektiösen rekombinierenden viren, virale wässrige suspension und ihre medizinische verwendung
WO2002086100A3 (en) Expression of core-glycosylated hcv envelope proteins in yeast
DE69719754D1 (de) Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
PL375113A1 (en) Casein derived peptides and uses thereof in therapy
WO2004074486A3 (en) Fusion proteins of interferon alpha muteins with improved properties
NZ508505A (en) Treatment of wounds using an Egr-1 transcription factor polypeptide
DE69833876D1 (de) Zusammensetzungen und methoden zur zielgerichteten abgabe von biologisch aktivenfaktoren
FR2724945B1 (fr) Vecteurs viraux et utilisation en therapie genique
TR199902866T2 (xx) Organo- koruyucu aktiviteye sahip yeni BPC peptid tuzlar�, haz�rlanmalar� ve terapide kullan�lmalar� i�in prosesler.
ATE405286T1 (de) Neue mittel zur linderung von motorischen störungen
DE3769497D1 (de) Mittel zur bekaempfung von phytopathogenen mikroben.
DE69712182D1 (de) Peptide und ihre verwendung in der therapie von krankheiten des zöliakie-formenkreises
CA2163805A1 (en) Novel activating factor of leukocytes
WO2024040030A3 (en) Treating protein misfolding disorders
ATE315082T1 (de) Myeloider koloniestimulierungsfaktor und verwendungen davon
ES2188754T3 (es) Componente b como cicatrizante.
DE50013908D1 (de) Zytotoxisches t-zellepitop des papillomavirus l1-proteins und seine verwendung in diagnostik und therapie

Legal Events

Date Code Title Description
8364 No opposition during term of opposition